Older, younger patients with metastatic pancreatic cancer have similar survival
the ONA take:
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy and receive fewer agents yet have similar overall survival compared with younger patients with metastatic disease, according to a recent study published online ahead of print in the Journal of Geriatric Oncology.
For the study, researchers at Fox Chase Cancer Center in Philadelphia, PA, sought to compare patterns of care and outcomes of patients with metastatic pancreatic cancer who are less than 65 years of age with those older than 65 years of age treated at their institution.
The researchers analyzed the medical records of 579 patients who were treated between 2000 and 2010. Results showed that patients older than 65 years were less likely to receive any chemotherapy for their cancer. In addition, those over 65 who were treated were less likely to receive more than 1 agent.
Researchers found that survival was comparable between the two cohorts. In both groups, a higher number of treatment agents and lung metastatases was associated with longer overall survival, while liver metastates were associated with worse survival.
The findings suggest that older patients with metastatic pancreatic cancer with good performance status should be encouraged to enroll onto clinical trials.
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy compared with younger patients with metastatic disease.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|